Literature DB >> 23979075

Severe acute radiation syndrome: treatment of a lethally 60Co-source irradiated accident victim in China with HLA-mismatched peripheral blood stem cell transplantation and mesenchymal stem cells.

Mei Guo1, Zheng Dong, Jianhui Qiao, Changlin Yu, Qiyun Sun, Kaixun Hu, Guangxian Liu, Li Wei, Bo Yao, Qiuhong Man, Xuedong Sun, Zhiqing Liu, Zhiwu Song, Chengze Yu, Ying Chen, Qingliang Luo, Sugang Liu, Hui-Sheng Ai.   

Abstract

This is a case report of a 32-year-old man exposed to a total body dose of 14.5 Gy γ-radiation in a lethal (60)Co-source irradiation accident in 2008 in China. Frequent nausea, vomiting and marked neutropenia and lymphopenia were observed from 30 min to 45 h after exposure. HLA-mismatched peripheral blood stem cell transplantation combined with infusion of mesenchymal stem cells was used at Day 7. Rapid hematopoietic recovery, stable donor engraftment and healing of radioactive skin ulceration were achieved during Days 18-36. The patient finally developed intestinal obstruction and died of multi-organ failure on Day 62, although intestinal obstruction was successfully released by emergency bowel resection.

Entities:  

Keywords:  HLA-mismatched stem cell transplantation; acute radiation syndrome; mesenchymal stem cell

Mesh:

Substances:

Year:  2013        PMID: 23979075      PMCID: PMC3951066          DOI: 10.1093/jrr/rrt102

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


INTRODUCTION

Acute radiation syndrome (ARS) following an accidental nuclear exposure often induces severe bone marrow aplasia, gastrointestinal syndrome, skin burns, lung injury and/or central nervous system failure. Although allogeneic stem cell transplantation (alloSCT) and hematopoietic cell cytokines such as granulocyte colony-stimulating factor (G-CSF) are used, most patients with severe ARS die of bone-marrow failure or multi-organ failure [1-6]. The therapeutic potential of bone-marrow-derived mesenchymal stem cells (MSCs) has been well documented through animal model studies and clinical research, e.g. to hasten hematopoietic recovery and promote tissue repair following radiation injury [7-10]. However, the use of MSCs combined with alloSCT for the treatment of ARS in humans has not yet been reported. This article records the outcome for one patient who was exposed to a 60Co source and received 14.5 Gy irradiation in an accident in Taiyuan, China in 2008. The patient was treated with an infusion of MSCs combined with HLA-mismatched peripheral blood stem cell transplantation, and achieved speedy hematopoietic recovery.

MATERIALS AND METHODS

The radiation accident occurred at about 13:20 on 11 April 2008 at a plant for irradiation of traditional Chinese medicine in Taiyuan, Shanxi Province, China. The victim was a 32-year-old man. There were four workers handling the Chinese medicines. At 13:36, one of them, as described in this report, saw a ‘blue light’ and found that the radiation source (cobalt source, source intensity of 18 000 Curie) was still in working position, rather than retracted to a safe location. The distance between the workers and the radiation source was 80–150 cm. They evacuated immediately to a safe place away from the scene. Frequent vomiting, facial flushing and fever (temperature 38.9°C) were observed 30 min after exposure for the victim, who was transferred to our hospital 14 h after exposure. On admission, he presented with diffuse skin erythema on hands, face and trunk, and his parotid glands were slightly swollen. At 2 h after exposure, his white blood cell (WBC) count was 14.2 × 109/l. At 45 h after exposure, his lymphocyte count had decreased to 0, bilirubin was 29.9 μmol/l, aminotransferase was 46μ/l, and urea was 10.4 μmol/l. Treatments to improve hematologic recovery and prevent infections included administration of granulocyte colony-stimulating factor (G-CSF), selective gastrointestinal tract sterilization, prophylactic antibacterial and antifungal reagents, and reverse isolation. On Day 4 after exposure, the patient developed diarrhea (60 ml per day) and signs of systemic inflammatory response syndrome such as thoracodynia, difficulty breathing, hypopiesia (blood pressure 84–56 mmHg) and hypoxemia (88% oxygen saturation). On Day 7 after exposure, the patient's general condition was improved, and hypopiesia and hypoxemia disappeared after treatment with methylprednisolone, oxygen and furosemide. However, his WBC count decreased to 0.1 × 109/l, and bone marrow taps showed hypocellular marrow with decreased erythroid, myeloid and megakaryocytic lineages. Bone marrow examination suggested that there was little hope for autologous hematopoietic reconstitution and the same results were obtained by dosimetry. Biological dosimetry estimated from the decline rate of WBC and lymphocytes was > 10Gy, Cytogenetic studies indicated 14.5 (11.4–17.9) Gy γ-radiation, depending on the method of γ-dose estimation (Table 1) [11]. However, there was no matched related donor available. In our hospital the patient received HLA-A, B, C, DR and DQ mismatched haplo-identical peripheral blood transplantation from his older brother, combined with mesenchymal stem cells. Fludarabine (100 mg) was administered as an emergency conditioning on Day 7. Mononuclear cells and CD34+ cells were infused (11.56 × 108/kg and 8.54 × 106/kg, respectively) on Day 8 after exposure. Cyclosporine A (CSA, 1.5 mg/kg, transvenously), mycophenolate mofetil (MMF, 30 mg/kg) and CD25 monoclonal antibody (20 mg) were used for graft-versus-host disease (GVHD) prophylaxis [12].
Table 1.

Dosimetry of the victim

MethodDosage (Gy)
Decline rate of WBC and lymphocytes>10
Dic + Rc14.5 (11.4–17.9) 15.3 (13.7–16.9)a
CBMN + NDI10–20
PCC-R12.4 (9.5–15.3)
Physics method9.8 (6.9–14.7)b

Dic + Rc = dicentris plus centric ring, CBMN + NDI = cytokinesis-block micronuclei plus nuclear division index, PCC-R = premature chromosome condensation rings. aData from bone marrow, and the remainder from peripheral blood. bDose estimated by a physics method from the physics group in our hospital.

Dosimetry of the victim Dic + Rc = dicentris plus centric ring, CBMN + NDI = cytokinesis-block micronuclei plus nuclear division index, PCC-R = premature chromosome condensation rings. aData from bone marrow, and the remainder from peripheral blood. bDose estimated by a physics method from the physics group in our hospital. Bone marrow MSCs derived from 10 unrelated, HLA-mismatched donors were given by intrabone marrow injection or subcutaneous injection into the left hand only on Days 3, 8, 14, 23, 32, 37 and 40, or at Days 28 and 31, respectively, after exposure (Table 2). All procedures for MSC culture were as described previously [12]. Briefly, bone marrow aspirates were collected, mononuclear cells (MNCs) were fractionated with a 1.077 g/ml Ficoll-Paque density gradient and then cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Rockville, MD) supplemented with 10% serum at 37°C in a humidified environment containing 5% CO2. After culturing for 24–48 h, non-adherent cells were removed and the adherent layer was further cultured until 70–80% confluence. Then MSCs were harvested and used at passages 3–5. The MSCs harvested were aliquoted and cryopreserved at −80°C in liquid nitrogen including 10% DMSO. When used, the frozen MSCs were thawed fast and melted completely with culture medium at 37°C.
Table 2.

Infusion of MSCs in the patient after exposure

FrequencyInfusion Time, DayDoses, Cells/2 ml
1aDay 31.1 × 107
2aDay 81.55 × 107
3aDay 1411 × 107
4aDay 236.3 × 107
5aDay 325.6 × 107
6bDay 285.5 × 107
7bDay 315.0 × 107
8aDay 375.1 × 107
9aDay 405.0 × 107

aBy intrabone marrow injection. bBy subcutaneous injection in the skin lesions.

Infusion of MSCs in the patient after exposure aBy intrabone marrow injection. bBy subcutaneous injection in the skin lesions. The surface markers of the MSCs were examined by a four-color flow cytometer (EPICSxL-MCL, Beckman Coulter, Fullerton, CA), and the result showed that these cultured cells expressed CD105, CD73, CD90, CD29, CD44 and CD166, but lacked expression of CD45, CD34, CD14, CD79a, HLA-DR, CD31 and CD106 surface molecules. Adipogenic differentiation was assessed by Oil Red O staining, and osteogenic differentiation was analyzed by the von Kossa method. MSCs were also examined for bacteria, fungus and mycoplasma contamination. On Day 11 after exposure, the patient developed alopecia (Fig. 1A), and diarrhea increased gradually to 150 ml per day. On Day 8 after transplantation, the WBC count had increased to 4.68 × 109/l. On Day 12 after transplantation, the WBC and platelet counts had increased to 38.5 × 109/l and 98 × 109/l, respectively (Fig. 2), and diarrhea had increased to 500 ml per day. Bone marrow aspiration showed an active proliferation with tri-lineage hematopoiesis. A stable donor graft was obtained and no rejection occurred. A sustained full donor chimerism (FDC) was observed on Days 12, 28 and 52 after transplantation in the peripheral blood cells and bone marrow cells by short tandem repeat-PCR (STR-PCR), chromosome analysis and HLA-genotyping methods [12].
Fig. 1.

Radiation damage in the patient after exposure. (A) head hair lost; (B) and (C) hands showing erythema and ulceration (days 24 and 44 after exposure, respectively); (D) extensive necrosis of the colon at the surgery.

Fig. 2.

Changes in the WBC and platelet count after exposure.

Radiation damage in the patient after exposure. (A) head hair lost; (B) and (C) hands showing erythema and ulceration (days 24 and 44 after exposure, respectively); (D) extensive necrosis of the colon at the surgery. Changes in the WBC and platelet count after exposure. On Day 16 after transplantation, the lung infection of the patient was cleared, but diarrhea had increased to 500 ml per day, and the skin erythema had progressed to blistering and ulceration (Fig. 1B and C). Treatment with hemostasis, acid suppression agents, Tacrolimus and CD25 monoclonal antibody was employed, but there was no response. On Day 22 after transplantation, the diarrhea had increased to 1200 ml per day and turned to bloody stools with frequent nausea, vomiting and abdominal pain. On Day 36 after transplantation, bloody stools increased to 3000 ml per day, however, the patient's radioactive skin blisters and ulceration on the left hand gradually improved. On Day 40 after transplantation, the bloody stools had further developed to intestinal paralysis, obstruction and shock (blood pressure 50/30 mmHg), although further therapies including high dose hemostasis, pituitrin and stronger support were employed. An emergency surgical operation was conducted and revealed a large amount of bleeding (5000 ml) in the abdominal cavity, complicated with an extensive necrosis and sloughing of the mucosa of the small intestine and the colon (Fig. 1D). A resection of the small bowel and colon was done successfully, in which 4/5 of the small intestine and colon was removed. On Day 2 after the surgery, the symptoms of diarrhea and bleeding subsided, and other intestinal functions recovered gradually, however, lung infection appeared, associated with high fever. Stronger antibiotics and supportive treatments were given but failed. On Day 12 after surgery, the patient developed sepsis, abscess, shock and disseminated intravascular coagulation. On Day 62 after exposure (Day 14 after the surgery), the patient died of multi-organ failure. The autopsy found degeneration, necrosis and loss of mucosal, epithelial and inherent glands in the whole digestive tract. Furthermore, pulmonary edema with local interstitial fibrosis and multiple fungal infarction foci in the heart and kidneys was also observed.

DISCUSSION

In the present case, we report on one patient who developed ARS after receiving high-dose radiation in an accident in China. Severe neutropenia, frequent nausea, vomiting, skin ulceration and high fever were observed after exposure, and the radiation dose was estimated to be 14.5 Gy (12.4–17.9 Gy) according to the chromosomes, micronuclei analysis, clinical signs and symptoms [13-16]. The patient was assigned to severity Grade H4 using the METREPOL approach, which suggested irreversible damage to the stem cell pool [3, 17, 18], and because of which the patient received an emergency HLA-mismatched stem cell transplantation combined with continuous infusion of bone marrow MSCs following conditioning with a single dose of fludarabine. The most important result of these positive findings was that the patient, who received a radiation dose > 10 Gy and was graded H4, achieved a speedy hematopoietic recovery, including recovery of WBC and platelet counts, improvement of his lung infection, and stable full donor engraftment without GVHD. This was in contrast to previous reports from the Chernobyl nuclear accident, the Tokaimura accident in Japan, and the Shanghai accident in China [3, 5, 6, 19]. It should be noted that conditioning with fludarabine and GVHD prophylactic with CSA, MMF and CD25 antibody might have played an important role in ensuring donor engraftment and prevention of GVHD [12, 20, 21]. Alternatively, several studies have shown that MSCs are able to repair injured tissues arising from accidental radiation exposure, hasten hematopoietic recovery, and prevent GVHD when infused simultaneously with MSCs [7–10, 22]. In this case, rapid hematopoietic recovery and healing of skin blisters on the left hand were observed concomitant with the continuous intrabone-marrow and subcutaneous injections of MSCs, suggesting a potential benefit of MSCs in radiation treatments. Literature has reported that all patients assigned to H4 using the METREPOL approach die within 60 days due to multi-organ failure [3, 17]. In this study, the treatments did not prevent gastrointestinal radiation damage from occurring, which eventually developed into intestinal obstruction, although hematopoietic recovery had been achieved. Although emergency bowel resection successfully released the intestinal obstruction, the patient died on Day 62 from multi-organ failure related to gastrointestinal radiation damage. These results suggested that HLA-mismatched peripheral blood stem cells and MSCs can be used successfully to rescue hematopoietic damage. Drugs or other cells for improvement of other organ damage, such as in the gastrointestinal tract, are urgently needed.

FUNDING

This work was supported by grants form the “863 Projects” of Ministry of Science and Technology of PR China (No. 2006AA02A109).
  22 in total

1.  Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.

Authors:  H Tamaki; K Ikegame; M Kawakami; T Fujioka; A Tsuboi; Y Oji; Y Oka; H Sugiyama; I Kawase; H Ogawa
Journal:  Leukemia       Date:  2003-10       Impact factor: 11.528

2.  Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome.

Authors:  Alain Chapel; Jean Marc Bertho; Morad Bensidhoum; Loic Fouillard; Randell G Young; Johanna Frick; Christelle Demarquay; Frédérique Cuvelier; Emilie Mathieu; François Trompier; Nicolas Dudoignon; Claire Germain; Christelle Mazurier; Jocelyne Aigueperse; Jade Borneman; Norbert Claude Gorin; Patrick Gourmelon; Dominique Thierry
Journal:  J Gene Med       Date:  2003-12       Impact factor: 4.565

3.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

4.  Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents.

Authors:  N-C Gorin; T M Fliedner; P Gourmelon; A Ganser; V Meineke; B Sirohi; R Powles; J Apperley
Journal:  Ann Hematol       Date:  2006-08-01       Impact factor: 3.673

5.  Early dose assessment following severe radiation accidents.

Authors:  R E Goans; E C Holloway; M E Berger; R C Ricks
Journal:  Health Phys       Date:  1997-04       Impact factor: 1.316

Review 6.  Radiation accidents and nuclear energy: medical consequences and therapy.

Authors:  R E Champlin; W E Kastenberg; R P Gale
Journal:  Ann Intern Med       Date:  1988-11-01       Impact factor: 25.391

7.  Landmark perspective: Acute radiation syndrome.

Authors:  S C Finch
Journal:  JAMA       Date:  1987-08-07       Impact factor: 56.272

8.  Initial medical management of patients severely irradiated in the Tokai-mura criticality accident.

Authors:  T Hirama; S Tanosaki; S Kandatsu; N Kuroiwa; T Kamada; H Tsuji; S Yamada; H Katoh; N Yamamoto; H Tsujii; G Suzuki; M Akashi
Journal:  Br J Radiol       Date:  2003-04       Impact factor: 3.039

9.  Bone marrow transplantation after the Chernobyl nuclear accident.

Authors:  A Baranov; R P Gale; A Guskova; E Piatkin; G Selidovkin; L Muravyova; R E Champlin; N Danilova; L Yevseeva; L Petrosyan
Journal:  N Engl J Med       Date:  1989-07-27       Impact factor: 91.245

10.  Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model.

Authors:  M Mouiseddine; S François; A Semont; A Sache; B Allenet; N Mathieu; J Frick; D Thierry; A Chapel
Journal:  Br J Radiol       Date:  2007-09       Impact factor: 3.039

View more
  9 in total

1.  Gastrointestinal acute radiation syndrome in Göttingen minipigs (Sus scrofa domestica).

Authors:  Thomas B Elliott; Nicolaas E Deutz; Jatinder Gulani; Amory Koch; Cara H Olsen; Christine Christensen; Mark Chappell; Mark H Whitnall; Maria Moroni
Journal:  Comp Med       Date:  2014-12       Impact factor: 0.982

Review 2.  Reported radiation overexposure accidents worldwide, 1980-2013: a systematic review.

Authors:  Karen Coeytaux; Eric Bey; Doran Christensen; Erik S Glassman; Becky Murdock; Christelle Doucet
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

3.  The Regenerative Effect of Bone Marrow-Derived Stem Cells on Cell Count and Survival in Acute Radiation Syndrome.

Authors:  Seyed Mahmood Reza Aghamir; Davood Mehrabani; Masoud Amini; Mohammad Amin Mosleh-Shirazi; Samaneh Nematolahi; Fatemeh Shekoohi-Shooli; Seyed Mohammad Javad Mortazavi; Iman Razeghian Jahromi
Journal:  World J Plast Surg       Date:  2017-01

4.  Medical management of acute radiation syndrome and associated infections in a high-casualty incident.

Authors:  Nicholas Dainiak
Journal:  J Radiat Res       Date:  2018-04-01       Impact factor: 2.724

5.  Intraoperative radiotherapy for breast cancer treatment efficiently targets the tumor bed preventing breast adipose stromal cell outgrowth.

Authors:  Stefanie Uhlig; Anne Wuhrer; Sebastian Berlit; Benjamin Tuschy; Marc Sütterlin; Karen Bieback
Journal:  Strahlenther Onkol       Date:  2020-02-06       Impact factor: 3.621

Review 6.  The Particle Radiobiology of Multipotent Mesenchymal Stromal Cells: A Key to Mitigating Radiation-Induced Tissue Toxicities in Cancer Treatment and Beyond?

Authors:  Alexander Rühle; Anca-Ligia Grosu; Nils H Nicolay
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 5.738

Review 7.  Will mesenchymal stem cells be future directions for treating radiation-induced skin injury?

Authors:  Zhuoqun Fang; Penghong Chen; Shijie Tang; Aizhen Chen; Chaoyu Zhang; Guohao Peng; Ming Li; Xiaosong Chen
Journal:  Stem Cell Res Ther       Date:  2021-03-12       Impact factor: 6.832

8.  The healing effect of bone marrow-derived stem cells in acute radiation syndrome.

Authors:  Seyed Mohammad Javad Mortazavi; Fatemeh Shekoohi-Shooli; Seyed Mahmood Reza Aghamir; Davood Mehrabani; Amirreza Dehghanian; Shahrokh Zare; Mohammad Amin Mosleh-Shirazi
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

9.  Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells.

Authors:  Lena Pinzur; Levent Akyuez; Lilia Levdansky; Michal Blumenfeld; Evgenia Volinsky; Zami Aberman; Petra Reinke; Racheli Ofir; Hans-Dieter Volk; Raphael Gorodetsky
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-10-18       Impact factor: 12.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.